Quick answer
Extended answer
What are the most common research questions about Tirzepatide?
Key facts
- Compound
- Tirzepatide
- Class
- Dual GIP / GLP-1 receptor agonist
- Half-life
- ≈ 5 days (human, SC)
- Use
- In-vitro reference standard
What is Tirzepatide?
Tirzepatide is a synthetic 39-residue linear peptide that agonises both the GIP receptor and the GLP-1 receptor — a dual incretin receptor agonist. It was first described by Coskun and colleagues in 2018 as LY3298176.
Who developed Tirzepatide?
Tirzepatide (LY3298176) was discovered and developed by Eli Lilly and Company, with the discovery publication authored by Coskun and colleagues in Molecular Metabolism in 2018.
What receptors does Tirzepatide activate?
Tirzepatide activates the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) — both class B G-protein-coupled receptors of the secretin family. It does not appreciably engage the glucagon receptor.
What is the structural formula of Tirzepatide?
Tirzepatide has the empirical formula C225H348N48O68 and an average molecular weight of approximately 4813.53 g/mol. Its CAS registry number is 2023788-19-2.
What is the backbone of Tirzepatide derived from?
Unlike GLP-1 analogues such as Semaglutide, Tirzepatide's 39-residue backbone is derived from GIP. This choice of scaffold — engineered to retain GIPR agonism while enabling GLP-1R agonism — is central to its dual-receptor pharmacology.
What modifications extend Tirzepatide's half-life?
Two structural features drive the extended half-life: α-aminoisobutyric acid substitutions at positions 2 and 13 confer resistance to dipeptidyl peptidase-4 (DPP-4) cleavage, and a C20 fatty-di-acid attached at Lys20 through a γGlu-2xOEG spacer supports reversible non-covalent binding to serum albumin.
What is the plasma half-life of Tirzepatide in humans?
The reported plasma half-life of Tirzepatide is approximately five days after subcutaneous administration, supporting once-weekly dosing regimens in clinical use.
How does Tirzepatide differ from Semaglutide?
Semaglutide is a mono-agonist selective for GLP-1R. Tirzepatide activates both GIPR and GLP-1R and is reported as an imbalanced or biased GLP-1R agonist with reduced β-arrestin recruitment relative to native GLP-1. The backbones differ (GIP-based vs GLP-1-based), as do half-life (~5 days vs ~7 days) and side-chain chemistry (C20 di-acid vs C18 di-acid).
How does Tirzepatide differ from Retatrutide?
Retatrutide is a triple agonist that activates GLP-1, GIP and glucagon receptors. Tirzepatide activates only GLP-1 and GIP receptors. The addition of glucagon-receptor agonism in Retatrutide is proposed to add contributions from hepatic and adipocyte glucagon signalling that Tirzepatide does not have.
What is biased agonism at GLP-1R?
Biased agonism describes a ligand's preference for one branch of a receptor's signalling output — typically G-protein coupling versus β-arrestin recruitment. Tirzepatide has been reported as a biased GLP-1R agonist that recruits less β-arrestin than native GLP-1 at matched receptor engagement.
What is the GIP-adipocyte axis?
GIPR is expressed on adipocytes, where GIP signalling modulates lipid handling and insulin sensitivity. Engagement of this GIP-adipocyte axis is one of the mechanistic features that distinguishes dual GIP / GLP-1 agonists from GLP-1 mono-agonists.
In which research trials has Tirzepatide been studied?
The SURPASS programme evaluates Tirzepatide in type 2 diabetes (including SURPASS-1 as monotherapy and SURPASS-2 head-to-head with Semaglutide). The SURMOUNT programme evaluates Tirzepatide for weight management (including SURMOUNT-1 in adults with obesity).
What is HbA1c and why does it matter in Tirzepatide research?
HbA1c (glycated haemoglobin) reflects average blood glucose over roughly the preceding two to three months and is the standard endpoint for glycaemic-control studies. HbA1c change is the primary metabolic endpoint in the SURPASS programme.
How is research-grade Tirzepatide supplied?
Oxford Research Peptides supplies Tirzepatide as a lyophilised solid at defined purity (target ≥ 98% by HPLC) with LC-MS identity confirmation. It is intended solely for in-vitro laboratory research.
How should Tirzepatide reference material be stored?
Lyophilised Tirzepatide is stored at −20 °C, desiccated and protected from light. Reconstituted stocks should be aliquoted into low-binding vials, held short-term at 2–8 °C, longer-term at −20 °C, and freeze-thaw cycles minimised.
What diluent is used to reconstitute Tirzepatide?
Sterile water or bacteriostatic water is used for laboratory reconstitution. The exact diluent should follow the receiving laboratory's SOP. Vortexing should be avoided; gentle swirling protects the peptide backbone.
Why does buffer albumin matter in Tirzepatide assays?
Tirzepatide's C20 fatty-di-acid side chain supports strong binding to serum albumin. Buffer albumin content therefore alters the free (unbound) fraction of ligand and shifts apparent EC50 values in cell-based assays. Buffer composition should be reported explicitly for cross-laboratory comparability.
What analytical methods characterise Tirzepatide?
Reversed-phase HPLC at 214 nm is the standard purity method. LC-MS confirms identity against the theoretical monoisotopic mass. Size-exclusion HPLC is used where aggregation of the acylated peptide is a concern.
Is Tirzepatide a medicine?
Approved Tirzepatide medicines (Mounjaro for type 2 diabetes; Zepbound for weight management) are prescription therapeutics regulated by the MHRA in the United Kingdom, the EMA in the European Union and the FDA in the United States. Research-grade Tirzepatide supplied by Oxford Research Peptides is not a medicine and is intended solely for in-vitro laboratory research.
Can Tirzepatide be used off-label?
Off-label prescribing is a clinical decision made by qualified healthcare professionals under national regulation and is outside the scope of research-standard peptide reference material. Oxford Research Peptides does not describe or endorse therapeutic use of research-grade material.
For deeper reading see the Tirzepatide monograph, What is Tirzepatide?, Mechanism of Action guide, GLP-1 receptor explained, Triple agonists explained, Semaglutide monograph and the Retatrutide monograph. Related glossary anchors: dual incretin agonism, GIP-adipocyte axis, satiety signalling, Gs protein, C20 fatty diacid, weekly dosing pharmacokinetics, SURPASS programme, SURMOUNT programme and HbA1c endpoint.
Evidence summary
- What is Tirzepatide?
Beginner-friendly research-focused introduction to Tirzepatide — a dual GIP / GLP-1 receptor agonist positioned between Semaglutide and Retatrutide in incretin pharmacology.
- Tirzepatide Mechanism of Action
Receptor-level explanation of Tirzepatide as a dual GIP / GLP-1 receptor agonist — dual cAMP / PKA signalling, biased β-arrestin engagement at GLP-1R, GIP-adipocyte biology and integrated satiety signalling.
- Tirzepatide FAQ
Comprehensive research-focused FAQ on Tirzepatide — identity, dual-receptor pharmacology, structural modifications, pharmacokinetics, laboratory handling, evidence base and regulatory status.
Research use only
Publication information
- Published
- 2026-11-05
- Updated
- 2026-11-05
- Reviewed
- 2026-11-05
- Version
- 1.0
Revision history
- v1.02026-11-05· Editorial Team
Initial publication of the Tirzepatide cornerstone cluster (Authority Sprint 3B).
Editorial standards
Content is reviewed against our editorial process for scientific accuracy, sourcing, and clarity. Read our editorial standards.
Conflict of interest
Next scheduled review: 2028-05-05. Our research methodology describes how the review is conducted.